Serum levels of olfactomedin 4: a biomarker for asthma control state in asthmatics.

Olfactomedin 4 (OLFM4) asthma biomarkers

Journal

Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978

Informations de publication

Date de publication:
Apr 2020
Historique:
entrez: 13 5 2020
pubmed: 13 5 2020
medline: 13 5 2020
Statut: ppublish

Résumé

Neutrophils are a key component of inflammation in asthma. Olfactomedin 4 (OLFM4) is produced by neutrophils and has been reported to be associated with asthma inflammation. We hypothesized that serum OLFM4 may be increased in asthmatic individuals and can assist with predicting asthma control state. A total of 79 individuals were enrolled from Shenzhen People's Hospital, China and divided into 3 groups: uncontrolled asthmatics (n=35), controlled asthmatics (n=14), and healthy controls (n=30). The serum OLFM4 level was measured by enzyme-linked immunosorbent assay (ELISA). Clinical characteristics (such as age, gender, allergy history, body mass index (BIM), and smoking history), clinical indicators (such as whole blood count, sputum neutrophil, sputum eosinophil, forced expiratory volume in one second as percentage of predicted volume (FEV1% pred), IgE level, high sensitivity C-reactive protein (hs-CRP), and fractional expiratory nitric oxide (FeNO) were measured and the three groups were compared. The correlation between OLFM4 and the clinical characteristics and indicators was then evaluated. Finally, stepwise multiple regression analysis was performed to determine the contribution of clinical characteristics and clinical indicators influencing serum OLFM4 level. Our results showed that the serum OLFM4 level was increased two-fold in the controlled asthma group (3,450.38±3,000.35 pg/mL) and three-fold in the uncontrolled asthma group (5,084.57±3,425.76 pg/mL), compared to the healthy control group (1,830.11±1,239.70 ng/mL) (P<0.001). We found a positive correlation between serum OLFM4 level and sputum neutrophils (P<0.001). OLFM4 was also found to be related to both hs-CRP level (P=0.007*) and blood neutrophil count (P<0.001). There were no significant associations identified between OLFM4 and age, gender, BMI, allergy, blood eosinophils, blood neutrophils, IgE, FeNO, or FEV1% pred. Serum OLFM4 levels were increased in patients with asthma (the controlled asthma and uncontrolled asthma groups). There was a significant correlation between serum OLFM4 and levels of sputum neutrophil and hs-CRP, and OLFM4 was also related to both Hs-CRP level and blood neutrophil count. Serum OLFM4 level may serve as a useful biomarker for assessing asthma control state in asthmatic adults.

Sections du résumé

BACKGROUND BACKGROUND
Neutrophils are a key component of inflammation in asthma. Olfactomedin 4 (OLFM4) is produced by neutrophils and has been reported to be associated with asthma inflammation. We hypothesized that serum OLFM4 may be increased in asthmatic individuals and can assist with predicting asthma control state.
METHODS METHODS
A total of 79 individuals were enrolled from Shenzhen People's Hospital, China and divided into 3 groups: uncontrolled asthmatics (n=35), controlled asthmatics (n=14), and healthy controls (n=30). The serum OLFM4 level was measured by enzyme-linked immunosorbent assay (ELISA). Clinical characteristics (such as age, gender, allergy history, body mass index (BIM), and smoking history), clinical indicators (such as whole blood count, sputum neutrophil, sputum eosinophil, forced expiratory volume in one second as percentage of predicted volume (FEV1% pred), IgE level, high sensitivity C-reactive protein (hs-CRP), and fractional expiratory nitric oxide (FeNO) were measured and the three groups were compared. The correlation between OLFM4 and the clinical characteristics and indicators was then evaluated. Finally, stepwise multiple regression analysis was performed to determine the contribution of clinical characteristics and clinical indicators influencing serum OLFM4 level.
RESULTS RESULTS
Our results showed that the serum OLFM4 level was increased two-fold in the controlled asthma group (3,450.38±3,000.35 pg/mL) and three-fold in the uncontrolled asthma group (5,084.57±3,425.76 pg/mL), compared to the healthy control group (1,830.11±1,239.70 ng/mL) (P<0.001). We found a positive correlation between serum OLFM4 level and sputum neutrophils (P<0.001). OLFM4 was also found to be related to both hs-CRP level (P=0.007*) and blood neutrophil count (P<0.001). There were no significant associations identified between OLFM4 and age, gender, BMI, allergy, blood eosinophils, blood neutrophils, IgE, FeNO, or FEV1% pred.
CONCLUSIONS CONCLUSIONS
Serum OLFM4 levels were increased in patients with asthma (the controlled asthma and uncontrolled asthma groups). There was a significant correlation between serum OLFM4 and levels of sputum neutrophil and hs-CRP, and OLFM4 was also related to both Hs-CRP level and blood neutrophil count. Serum OLFM4 level may serve as a useful biomarker for assessing asthma control state in asthmatic adults.

Identifiants

DOI: 10.21037/atm.2020.03.213 PMID: 32395538 PMC: PMC7210139
pubmed: 32395538
doi: 10.21037/atm.2020.03.213
pii: atm-08-07-494
pmc: PMC7210139
doi:

Types de publication

Journal Article

Langues

eng

Pagination

494

Commentaires et corrections

Type : CommentIn

Informations de copyright

2020 Annals of Translational Medicine. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.213). The authors have no conflicts of interest to declare.

Références

Caspian J Intern Med. 2016 Winter;7(1):37-42
pubmed: 26958331
Ann Transl Med. 2019 Oct;7(20):570
pubmed: 31807551
Allergy Asthma Proc. 2015 Jan-Feb;36(1):e1-8
pubmed: 25562547
Allergol Int. 2014 Jun;63(2):153-60
pubmed: 24759559
Nat Immunol. 2015 Jan;16(1):45-56
pubmed: 25521684
J Infect Dis. 2017 Apr 1;215(7):1040-1048
pubmed: 28186242
PLoS One. 2015 Jul 10;10(7):e0131927
pubmed: 26162090
J Leukoc Biol. 2012 Mar;91(3):495-500
pubmed: 22187488
Int J Cancer. 2009 Nov 15;125(10):2383-92
pubmed: 19670418
J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):283-287.e4
pubmed: 25609347
Curr Top Med Chem. 2016;16(14):1582-6
pubmed: 26420366
Cancer Metastasis Rev. 2016 Jun;35(2):201-12
pubmed: 27178440
Eur Respir J. 2015 Sep;46(3):622-39
pubmed: 26206872
J Allergy Clin Immunol. 2014 Apr;133(4):997-1007
pubmed: 24582314
Rev Chil Pediatr. 2015 May-Jun;86(3):206-13
pubmed: 26363862
Am J Respir Crit Care Med. 2017 May 15;195(10):1311-1320
pubmed: 27925796
Nat Med. 2017 Jun 6;23(6):658-659
pubmed: 28586342

Auteurs

Xingyuan Chen (X)

Department of Respiratory and Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University), Shenzhen Institute of Respiratory Diseases, Shenzhen 518003, China.

Khan Khalid (K)

Department of Respiratory and Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University), Shenzhen Institute of Respiratory Diseases, Shenzhen 518003, China.

Dandan Chen (D)

Department of Respiratory and Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University), Shenzhen Institute of Respiratory Diseases, Shenzhen 518003, China.

Chen Qiu (C)

Department of Respiratory and Critical Care Medicine, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University), Shenzhen Institute of Respiratory Diseases, Shenzhen 518003, China.

Classifications MeSH